POLIO
MCID: PLM031
MIFTS: 63

Poliomyelitis (POLIO)

Categories: Infectious diseases, Muscle diseases, Neuronal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 11 19 58 75 43 14 16 71
Polio 19 53 75
Infantile Paralysis 19 71

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

Childhood 58

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Poliomyelitis

GARD: 19 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical Poliomyelitis to partial or full paralysis. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced.

MalaCards based summary: Poliomyelitis, also known as polio, is related to nonparalytic poliomyelitis and paralytic poliomyelitis. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Disease and TGF-Beta Pathway. The drugs Edetate calcium disodium anhydrous and Iron have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skeletal muscle and bone marrow, and related phenotypes are vomiting and fatigue

Disease Ontology: 11 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Orphanet: 58 Poliomyelitis is a viral infection caused by any of three serotypes of human poliovirus, which is part of the family of enteroviruses.

Wikipedia: 75 Poliomyelitis, commonly shortened to polio, is an infectious disease caused by the poliovirus.... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 954)
# Related Disease Score Top Affiliating Genes
1 nonparalytic poliomyelitis 32.8 PI4KB ACBD3
2 paralytic poliomyelitis 32.5 TLR3 RASA3 PVR CD8A CD4 BTK
3 smallpox 31.0 TNF IFNG ICAM1
4 west nile encephalitis 30.9 TNF TLR3 RIGI IL10 IFNG IFNB1
5 facial paralysis 30.8 TNF CD8A CD4
6 encephalitis 30.8 TNF TLR3 RIGI IL10 IFNB1
7 aseptic meningitis 30.8 TNF IL10 CD8A CD4
8 myelitis 30.8 TNF IL10 IFNB1
9 meningitis 30.8 TNF IL10 IFNG ICAM1 HLA-B FCGR2A
10 neuritis 30.7 TNF IL10 IFNG
11 bell's palsy 30.7 TNF TLR3 CD8A CD4
12 mumps 30.6 TNF TLR3 IL10 IFNG IFNB1
13 tick-borne encephalitis 30.5 TLR3 CD8A CD4
14 human immunodeficiency virus type 1 30.5 TLR3 IL10 IFNG HLA-B CD4
15 respiratory failure 30.4 TNF TLR3 IL10 IFNG IFNB1 ICAM1
16 meningoencephalitis 30.4 TNF IL10 CD8A CD4
17 myocarditis 30.4 TNF TLR3 IL10 IFNG ICAM1 CD4
18 acquired immunodeficiency syndrome 30.4 TNF IL10 IFNG ICAM1 HLA-B FCGR3A
19 vaccinia 30.4 TNF IFNB1 ICAM1 HLA-B
20 acute asthma 30.4 TNF IL10 ICAM1 CD4
21 herpes simplex 30.3 TLR3 RIGI IFNB1 CD8A
22 graft-versus-host disease 30.3 TNF IL10 IFNG
23 syphilis 30.3 TNF CD8A CD4
24 osteomyelitis 30.3 TNF IL10 IFNG
25 acute disseminated encephalomyelitis 30.3 IFNB1 CD8A CD4
26 chronic fatigue syndrome 30.2 TNF IL10 IFNG CD8A CD4
27 optic neuritis 30.2 TNF IL10 HLA-B
28 acute flaccid myelitis 30.2 PVR PI4KB ACBD3
29 hepatitis b 30.2 TNF TLR3 RIGI IFNG IFNB1
30 myasthenia gravis 30.2 TNF IL10 IFNG HLA-B FCGR2A
31 rubella 30.2 TNF TLR3 RIGI IL10 IFNG IFNB1
32 japanese encephalitis 30.1 TLR3 RIGI IFNB1 CD8A CD4
33 ebola hemorrhagic fever 30.1 TNF TLR3 RIGI IL10 IFNB1 CD8A
34 viral encephalitis 30.1 TNF TLR3 RIGI IL10 IFNB1 CD8A
35 sleep apnea 30.1 TNF IL10 ICAM1
36 pulmonary edema 30.0 TNF IL10 ICAM1
37 common variable immunodeficiency 30.0 TNF IL10 IFNG HLA-B BTK
38 toxoplasmosis 30.0 TNF IL10 IFNG
39 brucellosis 30.0 TNF IL10 IFNG HLA-B
40 spondylitis 30.0 TNF IL10 IFNG HLA-B
41 pfeiffer syndrome 30.0 TNF IL10 CD8A CD4
42 viral infectious disease 30.0 TNF TLR3 RIGI IL10 IFNG IFNB1
43 penicillin allergy 30.0 IL10 IFNG HLA-B
44 immunoglobulin alpha deficiency 30.0 IL10 CD8A CD4
45 thrombocytopenic purpura, autoimmune 30.0 FCGR2A CD8A CD4
46 septic arthritis 29.9 TNF IL10 CD4
47 hepatitis a 29.9 TNF TLR3 IL10 IFNG CD4
48 epidemic typhus 29.9 IL10 CD8A CD4
49 actinomycosis 29.9 TNF IL10 CD4
50 spinal cord disease 29.9 TNF IL10 IFNB1 CD8A CD4

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

Human phenotypes related to Poliomyelitis:

58 30 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vomiting 58 30 Frequent (33%) Frequent (79-30%)
HP:0002013
2 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
3 fever 58 30 Frequent (33%) Frequent (79-30%)
HP:0001945
4 skeletal muscle atrophy 58 30 Frequent (33%) Frequent (79-30%)
HP:0003202
5 anorexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002039
6 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
7 myalgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003326
8 areflexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001284
9 meningitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001287
10 headache 58 30 Frequent (33%) Frequent (79-30%)
HP:0002315
11 hypoplasia of the musculature 58 30 Frequent (33%) Frequent (79-30%)
HP:0009004
12 muscle flaccidity 58 30 Frequent (33%) Frequent (79-30%)
HP:0010547
13 functional motor deficit 58 30 Frequent (33%) Frequent (79-30%)
HP:0004302
14 brisk reflexes 58 30 Frequent (33%) Frequent (79-30%)
HP:0001348
15 pharyngitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0025439
16 paralysis 58 30 Frequent (33%) Frequent (79-30%)
HP:0003470
17 nausea 58 30 Frequent (33%) Frequent (79-30%)
HP:0002018
18 stiff neck 58 30 Frequent (33%) Frequent (79-30%)
HP:0025258
19 exercise intolerance 58 30 Frequent (33%) Frequent (79-30%)
HP:0003546
20 lower limb muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
HP:0007340
21 myelitis 58 30 Frequent (33%) Frequent (79-30%)
HP:0012486
22 abnormal motor nerve conduction velocity 58 30 Frequent (33%) Frequent (79-30%)
HP:0040131
23 low self esteem 58 30 Frequent (33%) Frequent (79-30%)
HP:0031469
24 dysphonia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001618
25 dysphagia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002015
26 cranial nerve paralysis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006824
27 immunodeficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002721
28 bulbar signs 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002483
29 paresthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003401
30 fasciculations 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002380
31 respiratory failure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002878
32 paraparesis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002385
33 upper limb muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003484
34 inability to walk 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002540
35 bulbar palsy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001283
36 fatigable weakness of respiratory muscles 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030196
37 hyperkinetic movements 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002487
38 respiratory failure requiring assisted ventilation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004887
39 absent tonsils 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030813
40 diminished movement 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002374
41 impairment of activities of daily living 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031058
42 paralytic ileus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002590
43 hypotension 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002615
44 hypertension 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000822
45 irritability 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000737
46 coma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001259
47 confusion 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001289
48 agitation 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000713
49 hypovolemic shock 58 30 Very rare (1%) Very rare (<4-1%)
HP:0031274
50 infectious encephalitis 30 Very rare (1%) HP:0002383

GenomeRNAi Phenotypes related to Poliomyelitis according to GeneCards Suite gene sharing:

25 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 ACBD3 BTK CD4 CD8A DLG1 EIF4G1
2 no effect GR00402-S-2 10.13 ACBD3 BTK CD4 DLG1 FCGR2A FCGR3B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.96 PVR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.96 HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.96 PVR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.96 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.96 CD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-160 9.96 CD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.96 PVR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.96 PVR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.96 CD4 EIF4G1 PVR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.96 CD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.96 PVR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.96 PVR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.96 EIF4G1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.96 PVR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.96 PVR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.96 EIF4G1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.96 HLA-B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-94 9.96 EIF4G1

MGI Mouse Phenotypes related to Poliomyelitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 ACBD3 BTK CD4 DLG1 FCGR2A FCGR3A
2 nervous system MP:0003631 10.22 CD4 CD8A DLG1 EIF4G1 FCGR2A HLA-B
3 no phenotypic analysis MP:0003012 10.13 CD4 DLG1 EIF4G1 FCGR3A FCGR3B HLA-B
4 neoplasm MP:0002006 10.11 BTK ICAM1 IFNB1 IFNG IL10 PVR
5 immune system MP:0005387 10.09 BTK CD4 CD8A DLG1 FCGR2A FCGR3A
6 endocrine/exocrine gland MP:0005379 10.02 CD4 CD8A DLG1 FCGR2A HLA-B ICAM1
7 digestive/alimentary MP:0005381 9.96 BTK CD4 DLG1 FCGR2A HLA-B ICAM1
8 hematopoietic system MP:0005397 9.91 ACBD3 BTK CD4 CD8A DLG1 FCGR2A
9 mortality/aging MP:0010768 9.47 ACBD3 BTK CD4 CD8A DLG1 FCGR2A

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
2
Iron Approved Phase 4 7439-89-6 29936
3
Pentetic acid Approved Phase 4 67-43-6
4
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
5
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
6
Calcium carbonate Approved, Investigational Phase 4 471-34-1
7
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
8 Antibodies, Blocking Phase 4
9 PENTA Phase 4
10 Fibrinolytic Agents Phase 4
11 Anticoagulants Phase 4
12 Iron Chelating Agents Phase 4
13 Antidotes Phase 4
14 Chelating Agents Phase 4
15 Zinc Supplement Phase 4
16 Acidophilus Phase 4
17 Trace Elements Phase 4
18 Micronutrients Phase 4
19
Deferiprone Approved Phase 3 30652-11-0 2972
20
Framycetin Approved, Experimental, Vet_approved Phase 3 1404-04-2, 119-04-0, 3947-65-7 413349 8378
21
Polymyxin B Approved, Vet_approved Phase 3 1405-20-5, 1404-26-8 4868
22
Ethanol Approved Phase 3 64-17-5 702
23
Streptomycin Approved, Vet_approved Phase 3 57-92-1 19649
24
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
25
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
26 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
27 Somatomedin B Phase 3
28 Hemagglutinins Phase 3
29 Taxane Phase 3 108169
30 Immunoglobulins Phase 2, Phase 3
31 Antibodies Phase 2, Phase 3
32 Immunoglobulins, Intravenous Phase 2, Phase 3
33 gamma-Globulins Phase 2, Phase 3
34 Rho(D) Immune Globulin Phase 2, Phase 3
35 Polymyxins Phase 3
36 Vitamins Phase 3
37 Anti-Bacterial Agents Phase 3
38 Antibiotics, Antitubercular Phase 3
39 Vaccines Phase 3
40 Protective Agents Phase 3
41 Neuroprotective Agents Phase 3
42 Central Nervous System Stimulants Phase 3
43
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
44
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
45
Phenol Approved, Experimental Phase 2 108-95-2 996
46
Magnesium sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9
47 Epinephryl borate Phase 2
48 Calcium, Dietary Phase 2
49
Calcium Nutraceutical Phase 2 7440-70-2 271
50
Arginine Approved, Investigational, Nutraceutical Phase 1 74-79-3 6322

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan Unknown status NCT03286803 Phase 4
2 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
3 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Unknown status NCT04638985 Phase 4
4 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) Unknown status NCT04636827 Phase 4
5 Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone. Completed NCT01475539 Phase 4
6 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
7 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
8 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
9 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
10 Phase IV Safety Monitoring Study of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04220515 Phase 4
11 Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04224519 Phase 4
12 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
13 Cross-sectional Study to Assess Persistence of Immunity Conferred by a Single IPV Dose Administered in the Expanded Program on Immunization(EPI) Routine Immunization Schedule Completed NCT03723837 Phase 4
14 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
15 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
16 Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh Completed NCT02643368 Phase 4
17 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic Completed NCT02580201 Phase 4
18 A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs) Completed NCT01831050 Phase 4
19 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
20 Intestinal and Humoral Immunity of Monovalent Oral Poliovirus Vaccine Type 1 When Administered With and Without Fractional Inactivated Poliovirus Vaccine Completed NCT03722004 Phase 4
21 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
22 Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
23 Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh Completed NCT02412514 Phase 4
24 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
25 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
26 Duration of Priming and Antibody Decay With Full-dose Inactivated Poliovirus Vaccine (IPV) Administered With or Without Bivalent Oral Poliovirus Vaccine (bOPV) Completed NCT03202719 Phase 4
27 Sero-conversion Study for a Two-dose Schedule of Sabin Strain Inactivated Poliovirus Vaccine in China Completed NCT03546634 Phase 4
28 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
29 Evaluation of the Persistence of the Immunity in 4-year-old Children Previously Immunised With an Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al AJV (Picovax®) by Measuring the Response to an Additional Dose of IPV-Al AJV Completed NCT04448132 Phase 4
30 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
31 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
32 A Study of Immunogenicity and Seroconversion With Sabin Inactivated Polio Vaccine Schedules in China. Completed NCT03597919 Phase 4
33 Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study Completed NCT01244464 Phase 4
34 Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study Completed NCT01278433 Phase 4
35 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
36 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
37 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
38 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
39 Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines Completed NCT02847026 Phase 4
40 Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants. Completed NCT01695798 Phase 4
41 Immunogenicity and Safety of the Booster Dose of Polio Vaccine Immunization Using Sabin IPV or bOPV at Children Aged 4 Years With Different Three Sequential Schedules History by Sabin IPV or bOPV in China Completed NCT04576910 Phase 4
42 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
43 Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants Completed NCT01616693 Phase 4
44 a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine Completed NCT04051736 Phase 4
45 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
46 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
47 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
48 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
49 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants Completed NCT02521974 Phase 4
50 Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV Recruiting NCT03890497 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

Organs/tissues related to Poliomyelitis:

MalaCards : Spinal Cord, Skeletal Muscle, Bone Marrow, Kidney, Bone, Brain, Lung

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 22024)
# Title Authors PMID Year
1
Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. 53 62
19457934 2009
2
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. 53 62
18317803 2008
3
Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. 53 62
17517601 2007
4
Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. 53 62
16336935 2005
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. 53 62
15033568 2004
6
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. 53 62
14654644 2003
7
Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. 53 62
12970433 2003
8
Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. 53 62
14563307 2003
9
The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. 53 62
12220986 2002
10
Recent insights into poliovirus pathogenesis. 53 62
11597452 2001
11
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. 53 62
10777530 2000
12
Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. 53 62
9188553 1997
13
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. 53 62
9203668 1997
14
Identification of two determinants that attenuate vaccine-related type 2 poliovirus. 53 62
1847458 1991
15
Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. 53 62
2030351 1991
16
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. 53 62
2170026 1990
17
The resurgence of polio: The effect of the Covid-19 pandemic on polio eradication. 62
36471883 2023
18
Rare recurrences of poliomyelitis in non-endemic countries after eradication: a call for global action. 62
36084661 2022
19
Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. 62
35108152 2022
20
Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review. 62
34270376 2022
21
The progress of postapproval clinical studies on Sabin IPV. 62
34213408 2022
22
Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020). 62
35258415 2022
23
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy. 62
36178008 2022
24
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. 62
36164460 2022
25
Reminders of existing vaccine mandates increase support for a COVID-19 vaccine mandate: Evidence from a survey experiment. 62
35985888 2022
26
Is it just a cure? Re-evaluating the effects of prenatal exposure to the Great Chinese Famine on the risk of infectious diseases in adulthood. 62
36335705 2022
27
The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. 62
35044877 2022
28
May I Have This Dance: A Case-Series on the Acute Cardiometabolic Demand of Wheelchair Dancing in Recreational Dancers with Spinal Cord Injury. 62
36455111 2022
29
Highlights From Infectious Disease Week 2022-COVID-19, HIV, Monkeypox, and Polio. 62
36350667 2022
30
Sustainable financing for Immunization Agenda 2030. 62
36464542 2022
31
New Challenges in the Global Eradication of Polio. 62
36384782 2022
32
Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. 62
36400086 2022
33
Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. 62
36400075 2022
34
Development of an animal component free production process for Sabin inactivated polio vaccine. 62
36217423 2022
35
Strengthened surveillance revealed a rapid disappearance of the poliovirus serotype 2 vaccine strain in Madagascar after its removal from the oral polio vaccine. 62
35977919 2022
36
Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants. 62
35394898 2022
37
Polio. 62
36379554 2022
38
A Polio Epidemic Is Averted. 62
36261905 2022
39
Polio has recently been detected in places like London, New York, Ukraine and Israel-but what does it really mean to the global eradication effort? 62
36342124 2022
40
Polio outbreak: An ongoing but ignored public health emergency of international concern - Correspondence. 62
36332784 2022
41
Polio outbreak: A longest and ongoing global public health emergency. 62
36055552 2022
42
Global polio eradication; can we replicate the smallpox success story? 62
36426668 2022
43
Polio in New York: will it just go away? 62
36319024 2022
44
Immunity to poliovirus in Afghanistan: A household sampling method for serological assessment based on geographical information systems. 62
36468597 2022
45
Lessons from Vaccine-Related Poliovirus in Israel, UK and USA. 62
36423064 2022
46
Outbreak response strategies with type 2-containing oral poliovirus vaccines. 62
36402659 2022
47
What has been learned about COVID-19 vaccine hesitancy in Pakistan: Insights from a narrative review. 62
36425896 2022
48
Childhood immunization and age-appropriate vaccinations in Indonesia. 62
36333713 2022
49
Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines. 62
34914144 2022
50
Risk factors associated with non-vaccination in Gambian children: a population-based cohort study. 62
35696088 2022

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 TLR3 RIGI IL10 IFNB1 HLA-B FCGR3A
2
Show member pathways
13.5 TNF IL10 IFNG IFNB1 ICAM1 EIF4G1
3
Show member pathways
13.27 TNF RIGI IL10 IFNG IFNB1 ICAM1
4
Show member pathways
13.08 TNF TLR3 RIGI PVR IL10 IFNG
5
Show member pathways
12.81 BTK IFNB1 RIGI TLR3 TNF
6
Show member pathways
12.6 TNF IL10 IFNG IFNB1 HLA-B
7
Show member pathways
12.52 RIGI IFNG IFNB1 ICAM1 HLA-B EIF4G1
8 12.44 TNF TLR3 RIGI PVR IL10 IFNG
9
Show member pathways
12.41 TLR3 RIGI IFNG IFNB1
10
Show member pathways
12.16 TNF IFNG HLA-B FCGR3A
11 12.05 CD8A FCGR3A HLA-B ICAM1 PVR
12 11.95 TNF IFNG ICAM1 FCGR2A
13 11.91 TNF IL10 IFNG FCGR2A CD8A CD4
14
Show member pathways
11.88 TNF TLR3 IL10 IFNG CD4
15 11.85 TNF IL10 IFNG HLA-B
16
Show member pathways
11.84 TLR3 RIGI IFNB1
17
Show member pathways
11.82 TLR3 IFNG CD4
18
Show member pathways
11.77 FCGR2A IFNB1 IFNG TNF
19
Show member pathways
11.74 IFNB1 CD8A CD4
20 11.73 IFNG ICAM1 FCGR2A
21 11.73 TNF IL10 IFNG CD8A CD4
22 11.72 TNF IFNB1 ICAM1
23 11.69 TNF IL10 IFNG
24 11.68 CD4 EIF4G1 IFNG IL10 TLR3
25
Show member pathways
11.68 TNF IL10 IFNG IFNB1 DLG1 CD8A
26
Show member pathways
11.63 ICAM1 IFNG TNF
27 11.62 TNF IL10 ICAM1
28
Show member pathways
11.59 TNF IL10 IFNG
29 11.56 TNF CD4 BTK
30 11.56 TNF RIGI IL10 IFNB1
31 11.53 TNF IL10 ICAM1
32 11.5 TNF IL10 IFNG CD4
33 11.5 CD4 CD8A IFNB1 IFNG IL10 TNF
34 11.48 TNF IL10 ICAM1
35 11.46 CD4 IFNG IL10
36 11.43 TNF TLR3 IFNB1
37 11.38 IFNG IFNB1 ICAM1 HLA-B
38 11.36 IL10 FCGR3A FCGR2A CD4
40
Show member pathways
11.34 TNF IL10 IFNG
41 11.19 TNF IL10 IFNG
42 11.19 TNF PVR IFNG FCGR3A
43 11.12 TNF IL10 IFNG IFNB1 CD4
44 10.68 TLR3 RIGI

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.74 TNF TLR3 ICAM1 HLA-B FCGR3B FCGR3A
2 plasma membrane GO:0005887 9.74 TNF TLR3 ICAM1 HLA-B FCGR3B FCGR3A
3 membrane raft GO:0045121 9.65 TNF ICAM1 DLG1 CD4 BTK

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 10.36 IFNG IFNB1 HLA-B CD8A CD4 BTK
2 calcium-mediated signaling GO:0019722 10.1 TNF FCGR3A CD4 BTK
3 positive regulation of phagocytosis GO:0050766 10.09 TNF IFNG BTK
4 positive regulation of inflammatory response GO:0050729 10.09 TNF TLR3 IFNG BTK
5 positive regulation of chemokine production GO:0032722 10.08 TNF TLR3 IFNG
6 regulation of immune response GO:0050776 10.08 FCGR3B FCGR3A FCGR2A
7 response to exogenous dsRNA GO:0043330 10.04 IFNB1 RIGI TLR3
8 response to virus GO:0009615 10.02 IFNB1 IFNG RIGI TLR3 TNF
9 positive regulation of tumor necrosis factor production GO:0032760 10.02 TLR3 RIGI IFNG FCGR3A BTK
10 cell surface receptor signaling pathway GO:0007166 10 IFNG IFNB1 FCGR3B FCGR3A FCGR2A CD8A
11 microglial cell activation GO:0001774 9.99 TNF TLR3 IFNG
12 positive regulation of cytokine production GO:0001819 9.98 TNF TLR3 IL10 IFNG
13 defense response GO:0006952 9.97 TNF TLR3 IFNB1 HLA-B
14 positive regulation of interleukin-6 production GO:0032755 9.96 BTK IFNG RIGI TLR3 TNF
15 detection of virus GO:0009597 9.91 TLR3 RIGI
16 negative regulation of cytokine production involved in immune response GO:0002719 9.89 IL10 TNF
17 cellular response to exogenous dsRNA GO:0071360 9.88 TLR3 RIGI IFNB1
18 positive regulation of synoviocyte proliferation GO:1901647 9.86 TNF BTK
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.84 TNF IFNG
20 positive regulation of nitrogen compound metabolic process GO:0051173 9.83 TNF IFNG
21 chronic inflammatory response to antigenic stimulus GO:0002439 9.78 IL10 TNF
22 positive regulation of vitamin D biosynthetic process GO:0060557 9.76 IFNG TNF
23 immune system process GO:0002376 9.61 BTK CD4 CD8A FCGR2A FCGR3A HLA-B
24 immune response GO:0006955 9.47 TNF TLR3 IL10 IFNG HLA-B FCGR3B

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 9.43 FCGR3B FCGR3A FCGR2A
2 transmembrane signaling receptor activity GO:0004888 9.4 TLR3 ICAM1 FCGR3B FCGR3A FCGR2A CD4

Sources for Poliomyelitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....